原发性血小板增多症对血小板功能和血栓形成的影响及奥扎格雷钠预防血栓的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (595 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the changes of platelet function and its effect on thrombosis in patients with essential thrombocytosis (ET), and to analyze the effect of Sodium Ozagrel on thrombosis prevention. Methods Thirty-two patients with ET admitted to Shaanxi Provincial People′s Hospital ("our hospital" for short) from September 2014 to September 2017 were enrolled as the study object, and they were divided into two groups by random number table, 16 cases in each group. Patients in routine group were treated with routine therapy, while patients in study group were treated with Ozagrel Sodium on the basis of routine treatment. Another 20 healthy volunteers who received physical examination in our hospital during the same period were selected as control group. The levels of P-selectin (CD62P), anti-fibrinogen receptor monoclonal antibody (PAC-1), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α) and thrombosis rate of three groups were observed. Results Before treatment, there were no differences in levels of CD62P, PAC-1, TXB2 and 6-keto-PGF1α between the routine group and study group (P > 0.05), but they were significantly higher than those of the control group, the differences were statistically significant (P < 0.05). After treatment, the levels of CD62P, PAC-1, TXB2 and 6-keto-PGF1α in the study group were significantly lower than those in the routine group, but still higher than those in the control group, the differences were statistically significant (P < 0.05). The thrombosis rate in the study group was only 6.25%, which was significantly lower than 18.75% in the control group, the difference was statistically significant (P < 0.05). Conclusion The indexes of platelet function and activity in ET patients are significantly different from those in healthy person, and the incidence of thrombosis is significantly increased. Sodium Ozagrel can significantly improve the platelet status of ET patients, promote the therapeutic effect and reduce the incidence of thrombosis, which is worthy of clinical application and promotion.

Key words： Thrombocythemia major Platelet Thrombus Sodium Ozagrel

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Lan GAO Ying ZHANG Weihua HOU Limin GAO Qiuying

Cite this article:

LI Lan GAO Ying ZHANG Weihua HOU Limin GAO Qiuying. Effects of primary thrombocytosis on platelet function and thrombus formation and the clinical effect of Sodium Ozagrel in preventing thrombus[J]. 中国医药导报, 2019, 16(20): 145-147,151.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I20/145

[1] 谢晓玲.老年原发性血小板增多症患者Jak2基因v617f点突变检测的临床意义[J].中国老年学杂志，2017，37（18）：4614-4615.
[2] 杨娣娣，韩秀蕊，赵园，等.原发性血小板增多症骨髓病理及JAK2－V617 F突变分析[J].现代肿瘤医学，2016，24（19）：3108-3111.
[3] 付荣凤，刘晓帆，刘葳，等.125例中国年轻原发性血小板增多症患者的临床特点及预后分析[J].中国实验血液学杂志，2017，25（3）：837-842.
[4] 陈沫，侯丽君，刘增香，等.原发性血小板增多症患者的预后和生存分析[J].中国实验血液学杂志，2017，25（2）：510-516.
[5] Finazzi G，Carobbio A，Thiele J，et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria [J]. Leukemia，2012，26（4）：716-719.
[6] 李小妮.151例低危原发性血小板增多症患者的临床特点和血栓危险因素相关分析[J].内科急危重症杂志，2016， 22（5）：379-380.
[7] 雷瑚仪，韩素芳.阿司匹林对老年原发性血小板增多症血小板活化及血液流变学的影响[J].中国现代医学杂志，2015，25（11）：94-96.
[8] 吴明正，周泽平，文静，等.原发性血小板增多症的危险分层与治疗进展[J].实用医学杂志，2015，31（17）：2920-2921.
[9] 吴艳丽，卢岑，梁志伟，等.治疗性血小板清除术治疗原发性血小板增多症1例[J].血栓与止血学，2015，21（6）：412-413.
[10] 车菲菲，王晓冬，万纯黔，等.原发性血小板增多症钙网蛋白基因突变及与临床特征的关系[J].血栓与止血学，2016，22（5）：524-526.
[11] 葛振嵘，李秀芬.急性冠脉综合征合并继发性血小板增多症患者血栓事件的预防及治疗[J].中国全科医学，2016， 19（14）：1719-1721.
[12] 陈荣华.阿司匹林对老年原发性血小板增多症血小板活化及血液流变学的影响[J].临床研究，2016，24（11）：13-14.
[13] Barbui T，Finazzi G，Carobbio A，et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia （IPSET-thrombosis） [J]. Blood，2012，120（26）：5128-5133，5252.
[14] 彭育红.CALR基因突变引起的原发性血小板增多症合并急性心肌梗死1例[J].中华老年多器官疾病杂志，2017，16（5）：379-380.
[15] Campregher PV，Santos FP，Perini GF，et al. Molecular biology of Philadelphia-negative myeloproliferative neoplasms [J]. Rev Bras Hematol Hemoter，2012，34（2）：150-155.
[16] 付荣凤，李慧媛，薛峰，等.修订版国际血栓预测模型（IPSET）在746例中国成人原发性血小板增多症患者中的应用评价[J].中华血液学杂志，2017，38（2）：92-96.
[17] 崔智勇，段金玲，聂彦博，等.阿那格雷和羟基脲在治疗原发性血小板增多症中血栓形成风险的Meta分析[J].临床内科杂志，2016，33（11）：759-762.
[18] 刘宇宏，刘卉.以血栓为首发表现的青年原发性血小板增多症6例临床分析[J].血栓与止血学，2016，22（1）：77-78.
[19] 何深，匡霞.以血栓为首发的原发性血小板增多症33例临床分析[J].中国现代药物应用，2015，9（14）：42-43.
[20] 廖彩翔.干扰素联合阿司匹林在ET维持治疗中的应用分析[J].河北医学，2017，23（3）：504-508.